Eli Lilly to Work With OpenAI

<p>Eli Lilly and Company announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI&&num;8217&semi;s generative AI to invent novel antimicrobials to treat drug-resistant pathogens&period; Antimicrobial resistance &lpar;AMR&rpar; is one of the top public health and development threats across the global health landscape&period;<&sol;p>&NewLine;<p>&&num;8220&semi;Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked threat of antimicrobial resistance&comma;&&num;8221&semi; said Diogo Rau&comma; executive vice president and chief information and digital officer at Lilly&period; &&num;8220&semi;Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom&comma; purpose-built technologies in the battle against drug-resistant pathogens&period; This partnership underscores our commitment to addressing significant health challenges experienced by people around the world&period;&&num;8221&semi;<&sol;p>&NewLine;<p>AMR affects countries in all regions and at all income levels and is exacerbated by poverty and inequality&comma; particularly in low- and middle-income countries&comma; which results in the greatest impact and risk&period; The misuse and overuse of antimicrobials in humans&comma; animals and plants are the main drivers in the development of drug-resistant pathogens&comma; magnifying this threat to global health&period;<&sol;p>&NewLine;<p>&&num;8220&semi;We&&num;8217&semi;re excited to work with Lilly to find new ways to treat microbial infections&comma;&&num;8221&semi; said Brad Lightcap&comma; chief operating officer at OpenAI&period; &&num;8220&semi;Advanced AI has the potential to deliver innovative breakthroughs in pharma&comma; and we&&num;8217&semi;re committed to working together with industry leaders to deliver tangible benefits for patients&period;&&num;8221&semi;<&sol;p>&NewLine;<p>This collaboration with OpenAI supports Lilly&&num;8217&semi;s earlier commitment to fighting drug-resistant pathogens through its Social Impact Venture Capital Portfolio&period; In 2020&comma; the portfolio committed &dollar;100 million to the AMR Action Fund&comma; aiming to provide patients with two to four new antibiotics by 2030 and contribute the next line of defense against multi-drug-resistant pathogens&period; In April 2023&comma; the AMR Action Fund announced its latest investments in biotech companies targeting a range of infections&period;<&sol;p>&NewLine;